血塞通联合依达拉奉治疗脑梗死的临床疗效及其安全性

Clinical efficacy and safety of Xuesaitong combined with edaravone in the treatment of cerebral infarction

目的探讨血塞通联合依达拉奉治疗脑梗死的临床疗效及其安全性。方法选取十堰市郧阳区中医医院2017年1月—2018年11月收治的脑梗死患者70例,随机分为对照组和研究组,每组35例。对照组采取依达拉奉治疗,研究组在对照组基础上给予血塞通治疗。比较2组临床疗效,治疗前后血液流变学指标,包括血栓形成系数、神经功能缺损评分、红细胞聚集率、血浆比黏度;并比较2组入院到出院时间、不良反应发生率。结果研究组总有效率高于对照组(P<0.05)。治疗前2组血栓形成系数、神经功能缺损评分、红细胞聚集率、血浆比黏度比较,差异无统计学意义(P>0.05);治疗后研究组血栓形成系数、神经功能缺损评分、红细胞聚集率、血浆比黏度低于对照组,(P<0.05)。研究组从入院到出院时间短于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论血塞通联合依达拉奉治疗脑梗死的临床疗效确切,可有效改善病情,改善血液流变学指标全血浆黏度、血小板凝聚率,降低血栓形成系数,改善患者神经功能,且安全性较高。

Objective To investigate the clinical efficacy and safety of Xuesaitong combined with edaravone in the treatment of cerebral infarction.Methods A total of 70 cases of patients with cerebral infarction were selected from January 2017 to November 2018 in Yunyang Hospital of Traditional Chinese Medicine,which were randomly divided into control group and study group,35 cases in each group.The control group was treated with edaravone,and the study group was treated with Xuesaitong on the basis of the control group.The clinical efficacy,hemorheological indexes before and after treatment,including thrombosis coefficient,neurological deficit score,erythrocyte aggregation rate,whole plasma specific viscosity,and the time from admission to discharge and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was higher than the control group(P<0.05).Before treatment,there was no significant difference in thrombosis coefficient,neurological deficit score,erythrocyte aggregation rate and whole plasma specific viscosity between the two groups(P>0.05);after treatment,the thrombosis coefficient,neurological deficit score,erythrocyte aggregation rate and whole plasma specific viscosity of the study group were lower than the control group(P<0.05).The time from admission to discharge of the study group was shorter than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Xuesaitong combined with edaravone in the treatment of cerebral infarction has definite clinical effect,can effectively improve the condition,improve hemorheology indexes,whole plasma viscosity,platelet aggregation rate,reduce the thrombosis coefficient,improve the neurological function of patients,and with high safety.